Social media

By prioritising community engagement, enabling remote enrollment, and clearly communicating risks and benefits, researchers and sponsors can help create safer, more inclusive clinical trials for pregnant individuals. Exp...

Planning an Integrated Summary of Safety and Efficacy (ISS/ISE) submission can be demanding, especially when studies differ in format or terminology. This blog explains how early preparation and the right integration str...

Connect with ICON experts at #ObesityWeek, booth \#520 to learn about our proven success designing and executing early phase studies, supported by a robust database of overweight/obese volunteers and in-house clinical re...

Over the past five years, ICON has participated in over 840 oncology and haematologic malignancy, and 83 non-malignant haematology, clinical studies globally. Meet ICON experts at #ASH25, booth \#2161 to learn how our fl...

Discover how GMP manufacturing can improve trial outcomes, reduce risk, and support regulatory success. During this webinar we will discuss the differences between GMP and USP compounding, and feature expert-led case stu...

Weight loss alone no longer defines success in obesity trials. With new treatments like GLP-1s showing both fat and muscle loss, researchers are rethinking what meaningful improvement really means. To do so, they are tur...

Throughout Breast Cancer Awareness Month, our colleagues across global offices came together to support this important cause through a series of impactful initiatives, including awareness walks, educational workshops, an...

GLP-1 receptor agonists have established compelling evidence for the commercial value of multi-indication drug development beyond obesity. Conventional paradigms for drug development must shift in order to adapt to multi...

Smarter oversight starts with smarter tools. ICON’s latest blog shows how tech enables agile, risk-based quality management in clinical trials. Explore the future of RBQM: https://ow.ly/wrH550XgO1g

October is intimate partner violence awareness month (IPV). IPV affects millions globally, yet its impact on clinical trial participation and outcomes remains largely unexamined. As the industry continues to advance equ...

Latest issue out now. Keep up to date on the latest changes with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who have discovered the convenience of this free monthly publication by signing u...

New research shows that clinical trials with digital endpoints can be completed 3 to 5 months faster than those without. This can be a difference worth millions. But the benefits of leveraging digital don’t end there. R...